格隆汇1月5日｜A股市场脑机接口概念股全线飙升，其中，三博脑科、翔宇医疗、美好医疗20CM涨 停，熵基科技涨超18%，爱朋医疗、诚益通涨超17%，麦澜德涨超16%，博拓生物涨超15%，伟思医疗 涨超14%，狄耐克涨超12%，乐普医疗涨超11%，塞力医疗（维权）、岩山科技、荣泰健康、创新医 疗、南京熊猫（维权）、盈趣科技10CM涨停. 消息面上，马斯克近日在社交媒体上表示，其脑机接口公司Neuralink将于2026年开始对脑机接口设备进 行"大规模生产"。 | 代码 | 名称 | | 涨幅% ↓ | 总市值 | 年初至今涨幅%。 | | --- | --- | --- | --- | --- | --- | | 301293 | 三博脑科 | 1 | 20.01 | 146亿 | 20.01 | | 688626 | 翔宇医疗 | 1 | 20.00 | 116亿 | 20.00 | | 301363 | 美好医疗 | -06- | 20.00 | 164Z | 20.00 | | 301330 | 熵基科技 | 1 | 18.34 | 92.05 Z | 18.34 | | 300753 | 爰朋医疗 | ...

1月5日，脑机接口板块高开，创新医疗、三博脑科、南京熊猫、岩山科技、美好医疗涨停，倍益康涨超20%，翔宇医疗涨超15%，诚益通、麦澜德、爱朋医 疗涨超10%。 近日，美国企业家埃隆.马斯克在社交媒体上表示，其脑机接口公司Neuralink将于2026年开始大规模生产脑机接口设备，并转向更加精简和几乎完全自动化 的外科手术流程。 拓展阅读 从硅谷的手术机器人精准植入柔性电极，到中国实验室里"北脑二号"的千通道解码算法突破；从让瘫痪者用意识打游戏、发微博，到用超声波无创调控大脑 情绪——脑机接口不再只是科幻片的桥段，它正在医疗领域掀起新一轮技术浪潮。 2026年新年伊始，美国科技富豪马斯克在社交媒体上宣布，他的脑机接口公司Neuralink今年将开启"大规模量产"（high volume），并转向更精简、全自动化 的外科手术流程。 与此同时，中国的脑机接口公司也正在加速临床，并呈现多种技术路线并行的格局。一场集体"插脑"竞赛进入冲刺阶段。 海内外多种技术路线并行 在复旦大学附属华山医院，由毛颖院长带领的脑机接口团队在过去一年里完成了中国第一例"全植入式脑机接口"临床试验。患者"小董"（董辉）是一位因车 祸导致脊髓 ...

每经AI快讯，1月5日，沪指高开0.46%，深成指高开0.80%，创业板指高开0.84%，人脑工程、贵金属、 石油石化等板块指数涨幅居前。脑机接口概念表现活跃，创新医疗涨停，美好医疗、三博脑科20cm涨 停，倍益康、爱朋医疗、翔宇医疗涨超10%，博拓生物、伟思医疗跟涨。 （文章来源：每日经济新闻） ...

Market Overview - The A-share market welcomed the first trading day of 2026 with all three major indices opening higher, with the Shanghai Composite Index rising by 0.46% to 3986.97 points, the Shenzhen Component Index increasing by 0.8%, and the ChiNext Index up by 0.84% [1] Sector Performance - The market experienced a rise in oil and gas, as well as precious metals sectors, driven by renewed risk aversion following the U.S. military's swift action in Venezuela, capturing President Maduro [1] - The brain-computer interface sector opened strongly, with stocks such as Innovative Medical and Sanbo Brain Science hitting the daily limit up, as Elon Musk's Neuralink prepares for large-scale production of brain-computer interface devices [1]

Core Viewpoint - Neuralink plans to start large-scale production of brain-machine interface devices in 2026, with a focus on highly automated surgical procedures that eliminate the need to remove the dura mater for electrode insertion [2][4]. Group 1: Neuralink's Developments - Neuralink aims to simplify the surgical process and enhance efficiency and cost-effectiveness through automation, marking a significant advancement in invasive brain-machine interface technology [2][4]. - The company has completed a $650 million Series E funding round in 2025, achieving a valuation of approximately $9 billion [4]. - As of September 2025, 12 individuals have undergone Neuralink device implantation, with a total usage time exceeding 15,000 hours [4]. Group 2: Market and Industry Trends - The brain-machine interface market is projected to grow to approximately $12.4 billion by 2034, with a CAGR of 17% from 2025 to 2034 [5]. - The anticipated commercialization of brain-machine interfaces is expected to transition from medical necessity to applications in AI and robotics [2][5]. - Related companies in the A-share market are expected to benefit from Neuralink's scaling production and technological breakthroughs [5]. Group 3: Future Prospects - Neuralink's future product upgrades include increasing electrode channels to 3,000 by 2026 and 10,000 by 2027, with a long-term goal of over 25,000 channels by 2028 [4]. - The collaboration between Neuralink and the Optimus robot is expected to redefine human-robot interaction and explore the potential of integrating human brain functions with AI [3][4].

更多资料加入知识星球:水木调研纪要 关注公众号:水木纪要 脑机接口深度报告 20260104 摘要 Q&A 更多资料加入知识星球:水木调研纪要 关注公众号:水木纪要 接口的医保价格进行了单独立项,并有 11个省份跟进了相关费用的设定。7月 份,工信部联合七部门发布了《脑机接口推动产业创新发展实施意见》,在全国 范围内推广两步走的产业目标,并强调非侵入式产品在工业制造和安全生产中的 应用。10月28日,《十五规划建议》将脑机接口列为六大未来产业之一,并定 位为新的经济增长点。12月26日,国家药监局将植入式脑机接口器械纳入优先 审批高端医疗器械目录,这将加快相关产品的注册审批流程。 脑机接口全球市场规模如何测算? 我们对全球脑机接口市场规模进行了详细测算,将其划分为医疗和消费教育两大 类市场。目前医疗健康场景是主要关注点,包括运动功能障碍重建、语言功能障 碍重建、视觉障碍功能重建以及意识和认知障碍恢复等应用场景。在这些领域, 我们针对中风、癫痫、脊髓损伤、帕金森等疾病患者进行了渗透率假设。例如, 到 2030 年帕金森病领域渗透率预计可达 15%,到 2040 年整体渗透率可达到 15-20%。 消费教育领域虽 ...

Investment Rating - Investment rating: Positive (maintained) [1] Core Insights - Neuralink plans to initiate large-scale production of brain-machine interface devices in 2026, with a focus on automated surgical procedures, which is expected to accelerate the commercialization process [4][14] - The brain-machine interface industry is currently experiencing a high growth phase driven by technological breakthroughs, policy support, and expectations of ecological collaboration with robotics [7][72] - The global brain-machine interface market is projected to grow from approximately $2.94 billion in 2025 to about $12.4 billion by 2034, with a CAGR of 17.35% from 2025 to 2034 [68][72] Summary by Sections Section 1: Neuralink's Large-Scale Production and Technological Advancements - Neuralink is set to start large-scale production in 2026, utilizing a new automated surgical approach that avoids traditional invasive methods [14][15] - The company aims to upgrade its products rapidly over the next three years, with plans to demonstrate the potential for human-AI integration by 2028 [16][20] Section 2: Neuralink as a Leading Company in the Brain-Machine Interface Sector - Neuralink is a unicorn company in the brain-machine interface space, with a valuation of approximately $9 billion and a focus on invasive brain-machine technology [6][34] - The company has completed several human implant surgeries and is expanding its clinical trial applications [34][36] Section 3: Understanding Brain-Machine Interfaces - Brain-machine interfaces (BMIs) allow direct communication between the brain and external devices, functioning as a special communication system [53][54] - The technology is categorized into invasive, semi-invasive, and non-invasive types, each with its own advantages and risks [58][59] Section 4: Investment Logic and Beneficiary Stocks - The brain-machine interface industry is at a critical juncture, transitioning from laboratory research to commercialization, with significant market expansion potential [72] - Beneficiary stocks include companies like Sanbo Brain Science, Meihua Medical, and Innovation Medical, which are positioned to gain from the growth of the brain-machine interface sector [72][73]

Summary of Brain-Computer Interface Industry Update and Insights Industry Overview - The brain-computer interface (BCI) industry is in its early stages, with significant product approvals expected post-2028 and commercialization anticipated by 2030. Both China and the U.S. have implemented supportive policies for the sector, providing a crucial foundation for development [1][2][3]. Key Insights and Arguments - **Technological Advancements**: Continuous upgrades in technology, such as increased electrode channel counts, improved AI decoding algorithms, and the application of 5G and edge computing, are accelerating industry maturation. However, commercialization is primarily focused on non-invasive methods, resulting in low revenue for related companies [1][4]. - **Clinical Trials and Company Progress**: Companies like Neuralink, Syncro, Ladder Medical, and Borui Kang are under observation for their clinical trial advancements. Neuralink has accelerated its clinical trials, aiming to complete 20 trials by 2025, with 19 already enrolled. Borui Kang's Neo system has entered a special review process, achieving 1,312 implants with 100% improvement in hand function for all patients [1][6][7][10][11]. - **Market Risks and Investment Strategies**: While the long-term outlook for the BCI industry is positive, short-term bubble risks exist. Investors are advised to adopt a trading strategy and closely monitor national policy developments and key clinical trial progress from major companies [1][6]. Important but Overlooked Content - **Policy Support**: Both China and the U.S. have shown strong commitment to the BCI field, with China announcing a two-step strategy for the next five years and the U.S. providing policy and funding support. This guidance is crucial for the development of both invasive and non-invasive BCIs [3]. - **Company Comparisons**: Internationally, Neuralink and Syncro are benchmarks, with Neuralink focusing on invasive methods and Syncro offering a hybrid approach. Domestically, Ladder Medical and Borui Kang are making significant strides, with Ladder Medical's flexible electrode technology showing promise in clinical trials for high-level paraplegia and ALS [13][24]. Company-Specific Developments - **Neuralink**: Aims to enable paralyzed patients to perform physical actions independently by 2025, with ongoing clinical trials showing progress [8]. - **Singular**: Released a new model in 2025 that effectively decodes brain signals, enhancing the prediction of cognitive intentions [9]. - **Borui Kang**: The Neo system is on a fast track for commercialization, with significant clinical trial achievements [10][11]. - **Ladder Medical**: Demonstrated stability in signal transmission during clinical trials, with advancements in electrode technology [12]. - **New Wei Medical**: Expected to achieve over 40% revenue growth in 2025, targeting 1 billion RMB in revenue by 2028 [21]. Future Considerations - Investors should focus on policy directions and significant clinical trial outcomes, including the scale of trials and data disclosures from overseas companies, as well as the potential for multi-center trials from domestic firms like Ladder Medical [14]. Conclusion The BCI industry is poised for growth, driven by technological advancements and supportive policies. However, investors should remain cautious of short-term risks while keeping an eye on key developments within leading companies and the overall market landscape [6][24].

三博脑科医院管理集团股份有限公司 董事及高级管理人员薪酬管理制度 第一章 总则 (四) 体现激励和约束并重、奖罚对等的原则，薪酬发放与考核挂钩、 与奖惩挂钩。 第二章 考核管理 第四条 公司董事会下设薪酬与考核委员会，负责制定董事、高级管理人员 的考核标准并进行考核，制定、审查董事、高级管理人员的薪酬政策与方案。 1 / 5 第五条 公司人力资源部、财务部等相关部门配合薪酬与考核委员会进行公 司董事、高级管理人员薪酬方案的具体实施。 第一条 为进一步完善三博脑科医院管理集团股份有限公司（以下简称"公 司"）董事、高级管理人员的薪酬管理，建立科学有效的激励约束机制，充分调 动其工作积极性和创造性，确保公司战略目标的实现，根据《中华人民共和国公 司法》《上市公司治理准则》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》等相关法律法规、规范性文件以及《三博脑科医院 管理集团股份有限公司章程》（以下简称"《公司章程》"）的有关规定，结合 公司实际情况，特制订本制度。 第二条 本制度适用于公司全体董事（含独立董事）及高级管理人员（总经 理、副总经理、财务总监、董事会秘书）。 第三条 公司董事 ...

证券代码：301293 证券简称：三博脑科 公告编号：2025-053 三博脑科医院管理集团股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2026 年第一次临时股东会 2、股东会的召集人：董事会 4、会议时间： （1）现场会议时间：2026 年 01 月 16 日 15:30:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 01 月 16 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的 具体时间为 2026 年 01 月 16 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2026 年 01 月 09 日 7、出席对象： （1）于股权登记日下午收市时在中国结算深圳分公司登记在册的公司全体已发行有 表决权股份的股东均有权出席股东会，并可以以书面形式委托代理人出席会议和参加表决， 该股东代理人不必 ...